Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Roche Holding Ltd. : UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding AG and Reminds Investors with Losses to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 10:03pm CEST

IRVINE, CA / ACCESSWIRE / July 17, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Roche Holding AG ("Roche Holding" or the "Company") (OTCQX: RHHBY). Investors, who purchased or otherwise acquired shares from March 2, 2017 through June 5, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the August 7, 2017 lead plaintiff motion deadline.

If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose material information, specifically that the combination of the Company's breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher rate of side effects. Following this news, Roche Holding's stock price dropped materially, causing investors harm according to the Complaint.

If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP


© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
07/26 ROCHE : Positive Phase III Results of Genentech’s Actemra (Tocilizumab) fo..
07/26 ROCHE HOLDING LTD. : DEADLINE ALERT: Khang & Khang LLP Announces Securities Clas..
07/26 ROCHE HOLDING LTD. : RHHBY The Law Offices of Vincent Wong Reminds Investors of ..
07/26 ROCHE HOLDING LTD. : DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds ..
07/25 ROCHE HOLDING LTD. : Levi & Korsinsky, LLP Notifies Shareholders of Roche Holdin..
07/25 REMINDER : Invitation to Roche Analyst Event on Diagnostics Division at AACC 201..
07/24 ROCHE HOLDING LTD. : TWO WEEK DEADLINE: Lundin Law PC Announces Securities Class..
07/24 ROCHE HOLDING LTD. : IMMINENT ROCHE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faru..
07/24 ROCHE HOLDING LTD. : The Klein Law Firm Reminds Investors of a Class Action File..
07/24 ROCHE : CRICKET-U19s-SCOREBOARD Zimbabwe U-19s vs Zimbabwe U-19s - 1st YODI
More news
News from SeekingAlpha
07/26 Pfizer Doesn't Want To Be Left In the Dust Of Avastin Biosimilar
07/26 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 26, 2017
07/26 2 Cheers For Biogen, Which May Be Good Enough To Allow Alpha
07/26 Danaher In Some Doldrums
07/25 Don't Lose The Faith In Shire
Financials ( CHF)
Sales 2017 53 066 M
EBIT 2017 18 191 M
Net income 2017 11 382 M
Debt 2017 9 070 M
Yield 2017 3,54%
P/E ratio 2017 17,72
P/E ratio 2018 16,49
EV / Sales 2017 4,13x
EV / Sales 2018 3,88x
Capitalization 210 335 M
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 282  CHF
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.4.30%220 599
JOHNSON & JOHNSON14.47%355 263
NOVARTIS7.35%220 651
PFIZER1.91%197 115
MERCK AND COMPANY5.93%170 565
SANOFI7.50%121 268